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Summary 
Transgenic FVB/N mice overexpressing human (Hu) 
or mouse (Mo) Alzheimer amyloid precursor protein 
(APPsgs) die early and develop a CNS disorder that in- 
cludes neophobia and impaired spatial alternation, 
with diminished glucose utilization and astrogliosis 
mainly in the cerebrum. Age at onset of neophobia and 
age at death decrease with increasing levels of brain 
APP. HuAPP transgenes induce death much earlier 
than MoAPP transgenes expressed at similar levels. 
No extracellular amyloid was detected, indicating that 
some deleterious processes related to APP overex- 
pression are dissociated from formation of amyloid. 
A similar clinical syndrome occurs spontaneously in 
-20% of nontransgenic mice when they reach mid- 
to late-adult life, suggesting that APP overexpression 
may accelerate a naturally occuring age-related CNS 
disorder in FVB/N mice. 
Introduction 
Age and genes, either as specific alleles (e.g., ApoE4) 
or as mutants (e.g., amyloid precursor protein [APP] and 
$182), are the major risk factors for Alzheimer's disease 
(AD). Patients with AD exhibit to a greater degree abnor- 
malities that are similar to those occurring in the brains of 
many nondemented elderly individuals, including amyloid 
deposits, neurofibrillary tangles, reductions in numbers of 
neurons and synapses in certain regions, and astrocytic 
gliosis (Crystal et al., 1988; Arriagada et al., 1992). The 
incidence of AD increases dramatically in late life, with as 
many as 47% of those over the age of 85 having AD (Evans 
et al., 1989; Kokmen et al., 1989). Because mild cognitive 
deficits and some of the histologic manifestations of AD 
are present in aged individuals without AD, there is specu- 
lation that similar processes may occur in both mildly im- 
paired, aged individuals and cases of AD. 
Genes on chromosomes 21, 19, 14, and 1 are associ- 
ated with AD (Goate et al., 1991 ; Corder et al., 1993; Levy- 
Lehad et al., 1995; Sherrington et al., 1995). The APP 
gene on chromosome 21 encodes a transmembrane pro- 
tein expressed in brain and other tissues, and five muta- 
tions in this gene can cause early onset familial AD (Char- 
tier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 
1991; Hendriks et al., 1992; Mullan et al., 1992). All five 
mutations occur within or near the #-amyloid (AI3) domain, 
a 4 kDa fragment present in amyloid, and these mutations 
may influence APP processing to facilitate amyloid forma- 
tion. In cultured cells, APP with the V7171 mutation is asso- 
ciated with an increase in the AI31-42 peptide (Suzuki et al., 
1994), while APP with K670N-M671 L, termed the Swedish 
mutation, is associated with increased AI31-40 secretion 
(Citron et al., 1992; Cai et al., 1993). These results support 
the argument hat events related to the processing of APP 
and the generation of AI3 underlie the CNS dysfunction in 
early onset familial AD. Patients with trisomy 21 (Down's 
syndrome) overexpress APP and develop AD-like pathol- 
ogy and cognitive decline, often before the fifth decade, 
indicating a role for APP overexpression. While the evi- 
dence supporting the involvement of APP and AJ3 in AD 
is compelling, how these molecules are related to the neu- 
rologic dysfunction of AD remains controversial. To inves- 
tigate the biologic effects of overexpression of APP with 
or without AD-linked mutations, we produced Tg mice ex- 
pressing either wild-type or mutant APP. We reasoned 
that both wild-type and mutant APP might induce early 
neurologic dysfunction in Tg mice, since the presence of 
extra copies (Down's syndrome) or mutations (familial AD) 
is associated in humans with early onset AD-like pathol- 
ogy. Because the senescent changes that occur in many 
elderly individuals resemble sporadic AD, we also exam- 
ined aged non-Tg mice. 
FVB/N mice were chosen because they are an inbred 
strain with prominent pronuclei n single-cell embryos and 
high fertility, making them useful for transgenic ap- 
proaches (Taketo et al., 1991). FVB/N mice are related 
to the Swiss stock. All Tg lines that overexpressed APP, 
whether mutant or wild type, died early and developed a 
neurologic syndrome similar to that seen in some aged 
FVB/N mice. 
Results 
PrP Cosmid Vector Drives Overexpression 
of APP in Transgenic Mice 
To determine the effect of mutant and wild-type APP ex- 
pression in FVB/N mice, we replaced the prion protein 
(PrP) open reading frame (ORF) with a variety of APP 
ORFs in a hamster PrP cosmid vector (Scott et al., 1992), 
which has been shown to drive position-independent, copy 
number-dependent transgene product expression in the 
brain (Scott et al., 1989; Prusiner et al., 1990; Westaway 
et al., 1994). Tg mice harbored one of four different 
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(C) Coomassie stain of protein in brain extracts shown to control for protein loading. 
Figure 1. Transgenic APP Protein Expression 
in Brain Tissue 
Transgenic APP protein expression was mea- 
sured in a semiquantitative fashion in 4 lines 
of Tg mice, Tg(HuAPP69s.WTmyc)466, Tg 
(HuAPP695.TRImyc)1056, Tg(HuAPP69s.TRImyc) 
1118, and Tg(HuAPP69s.TRImyc)1130H, har- 
boring 26, 7, 21, and 74 transgene copy num- 
bers, respectively. Equivalent amounts of 
protein from detergent-extracted brain homog- 
enates of non-Tg and Tg (asterisks) littermates 
were immunoblotted in parallel. Equivalent 
amounts of protein from detergent-extracted 
brain homogenates ofnormal human (lane 9) 
and AD (lane 10) brain were immunoblotted. 
Primary antibody was revealed by ~2Sl-protein 
A. For monoclonal ntibodies, blots were first 
incubated with rabbit antiserum to mouse IgG. 
The amount of bound 'aSl-protein A was quanti- 
fied using a phosphorimager, demonstrating 
a direct relationship between transgene copy 
number and transgene product expression. 
(A) To measure the level of HuAPP specifically, 
brain homogenates were probed with 6E10 an- 
tibody raised against residues 1-17 of human 
A!3 (Kim et al., 1990). 
(B) Relative levels of transgenic ompared with 
endogenous brain MoAPP were examined by 
immunoblot analysis with a monoclonal anti- 
body, 22C11, which detects both HuAPP and 
MoAPP. 
(D) The relative amount of HuAPP in 10% (w/v) homogenates of various brain regions was specifically detected in Tg(HuAPP69s.TRImyc)1130H 
mice using the 6E10 antibody, as described above. Equivalent amounts of protein were immunoblotted in each lane. The highest HuAPP level, 
in the cerebrum, was approximately twice that of the cerebellum. 
(E) No difference in expression of PrP was found in 100/o (w/v) homogenates of brain tissue from Tg mice harboring 21,26, or 74 transgene copies 
and nontransgenic littermates using the antiserum R073. 
transgenes, some containing mutations associated with 
familial AD (MoAPP69~.WT [wild type]; HuAPP695.SWE 
[K670N and M671L, APP770 numbering]; HuAPP69s.TRI- 
myc [V7171, V721A, and M722V with a 3'-myc tag]; HuAP- 
P69s.WTmyc [wild type with a 3'-myc tag]; Mo, Mouse; Hu, 
Human). Initially, we introduced transgenes with a 3'-myc 
tag, a 12 codon segment of the c-myc proto-oncogene, to 
facilitate immunodetection of transgene products (Wong 
and Cleveland, 1990). The myc tag exerted no apparent 
effect on the phenotype, since Tg(HuAPP69s.SWE) mice 
lacking the myc tag developed the same clinical and patho- 
logic features. In later studies, the high level of APP ex- 
pression obtained in our mice obviated the need for the 
myc tag. The experimental V721A and M722V mutations, 
unintentionally introduced to the APP ORF harboring the 
V7171 mutation linked to early onset familial AD and dis- 
covered after Tg lines had been established, exerted no 
obvious effect on the phenotype since Tg(HuAPP69s.TRI- 
myc) mice developed the same clinical and pathologic 
abnormalities as Tg mice expressing the other three 
transgenes. Subsequent analyses of HuAPP69s.TRImyc in 
cultured cells indicated that these unintentional mutations 
exert no significant effects on the processing of HuAPP 
relative to protein maturation, modification, or proteolytic 
processing to produce soluble ectodomains or AI3 pep- 
tides (D. R. B., G. Thinakaran, and S. Sisodia, unpublished 
data). 
APP expression was measured in brains of Tg mice 
harboring different transgene copy numbers by quantita- 
tion of immunoblots in Tg lines with the monoclonal anti- 
body 22C11 (Weidemann et al., 1989), which recognizes 
an identical epitope in both mouse and human APP (Figure 
1B) as well as amyloid precursor-like protein 2 (APLP2), 
potentially leading to an underestimation of the amount 
of Tg APP relative to endogenous MoAPP (Slunt et al., 
1994). APP protein expression in Tg brain depended upon 
copy number as well as the species of APP expressed 
(Figure 2). MoAPP transgenes achieved levels equivalent 
to those of HuAPP transgenes, but with fewer copies. 
Measurement of AI3 in Tg(HuAPP69~.TRImyc) mice indi- 
cates that both A[31-40 and AI31 42 are generated in the brain 
(Table 1). A[3 levels were not measured in Tg FVB/N mice 
expressing HuAPP.SWE because of insufficient numbers 
of mice, owing to their poor breeding characteristics, and 
A6 levels were not measured in Tg mice expressing 
MoAPP because methods for reliably measuring mouse 
AI3 in the brain are not yet available. The Ban50 capture 
antibody does not recognize MoAPP; levels indicated for 
non-Tg mice represent background signal. Both forms of 
AI5 were readily detectable in Tg mice but were signifi- 
cantly higher in lines overexpressing APP and exhibiting 
clinical abnormalities than in an unaffected line expressing 
lower levels of APP. 
Specific immunostaining for human APP/AI~ using the 
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Figure 2. Dependence of Transgenic Brain APP Expression upon Transgene Species and Copy Number 
Tg brain MoAPP (squares) and HuAPP (circles and diamonds) expression increases with rising transgene copy numbers. Total brain APP, detected 
with 22C11 antibody, was determined in 3 Tg mice from each line and 9 non-Tg age-matched mice. Tg brain APP was calculated by the ratio of 
total APP in Tg mice compared with non-Tg mice, minus 1. Both Tg HuAPP and Tg MoAPP were quantified by this method. MoAPP is more 
efficiently expressed than HuAPP. Nonspecific effects of the hamster PrP cosmid vector driving APP expression were not the cause of clinical 
abnormalities in Tg FVB/N mice overexpressing APP, since a previously published Tg line developed in FVB/N mice, Tg(HuPrP)FVB-152 (triangle), 
expressing human PrP driven by 30-50 copies of the hamster PrP gene cosmid exhibited no behavioral abnormalities or early death (Telling et 
al., 1994). 
8E5 or 6E10 monoclonal antibodies revealed HuAPP in 
vescicular structures within large pyramidal cells of the 
hippocampus, parahippocampal area, amygdala, and ce- 
rebral cortex, as well as fainter staining throughout the 
brain in smaller neurons and some glial cells. Antibody 8E5 
(gift of Dale Schenk, Athena Neurosciences) recognizes 
a segment of APP spanning residues 519-667 (APPTz0 
numbering), and 6E10 recognizes residues 1-17 of human 
A6 (Kim et al., 1990). The pattern of HuAPP immunostain- 
ing matched that of regional brain immunoblots showing 
the highest levels of expression in the cerebrum (see Fig- 
ure 1D). The brain and spinal cord contained the highest 
levels of HuAPP; the striated muscle, heart, skin, and lung 
<5% of brain levels; and the thymus, liver, spleen, kidney, 
testes, and small intestine undetectable amounts (data 
not shown). 
PrP levels remained unchanged in animals with high 
transgene copy numbers (see Figure 1E), indicating that 
the PrP promoter and other sequences in the transgenes 
did not deplete transcription factor pools, and that the cel- 
lular machinery for synthesizing, modifying, and translo- 
cating membrane glycoproteins was not overburdened. 
Poor Reproductive Ability and Early Death in Tg 
FVB/N Mice Overexpressing APP 
Of 19 founders identified, 7 failed to produce viable lines 
owing to death of the founder or poor fertility and short 
lifespan. FVB/N mice harboring >40 copies of the 
HuAPP695.SWE transgene bred poorly and died within a 
year; only 1 of 5 founders produced offspring, Tg2123H. 
Tg2123H mice bred erratically, preventing full character- 
ization of the line. Early clinical signs and death prevented 
Table 1. Brain A6 Levels in Transgenic Mice Expressing HuAPP.TRImyc 
Level of Tg APP Expression Animal Status n Age (days) AI~ 4o (pmol/g) A1~,-42 (pmol/g) 
Non-Tg WelP 11 81.1 _+ 10.2 0.85 -+ 0.36 0.18 -+ 0.10 
Low Well 2 109 1.56 0.5 
High Well 3 34 _+ 0 7.95 _+ 0.96 4.74 _.+ 0.67 
High Affected b 4 93.3 -+ 7.9 12.27 _+ 1.07 3.23 _+ 1.41 
Animals with high levels of Tg APP expression were selected from Tg1130H and Tg1140, animals with low levels of Tg APP expression were 
selected from Tg1056. Where applicable, values are mean _ SEM. 
a Corner index scores > 1. 
b Animals failed corner index testing (two scores of "0" or a "0" and "1" in three consecutive testing sessions). 
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breeding beyond the first generation in founders and lines 
harboring >74 copies of HuAPPe9s.TRImyc and in 1 line 
of mice harboring 26 copies of MoAPP69s.WT. These ob- 
servations indicate that overexpression of Tg APP beyond 
a critical level is highly deleterious, precluding the estab- 
lishment of permanent lines (Table 2). 
Death rates depended directly upon levels of APP ex- 
pression (Table 2; see Figure 4a). To assess the relative 
effects of transgenes with distinct genotypes, we deter- 
mined the incidence of death during the first 100 days of 
life in lines expressing different levels of HuAPP or MoAPP. 
Death rates were higher in Tg mice expressing mutant and 
wild-type HuAPP than in Tg mice expressing comparable 
levels of wild-type MoAPP. Comparisons of Tg mice ex- 
pressing mutant versus wild-type HuAPP were not possi- 
ble over the full range of APP expression. In most lines 
(e.g., Tg6209 and Tgl 118), a fraction of animals survived 
long term (>250 days). The longevity of these survivors 
extended beyond that predicted by survival curves derived 
from other mice in the same line (Figure 3). 
In <10% of animals, death followed a period of several 
days during which the mice were ungroomed, kyphotic, 
hypothermic, cachexic, and unresponsive when touched 
or gently prodded. About 140/0 of Tg(HuAPP69s.TRImyc) 
mice overexpressing APP exhibited agitation, thigmo- 
taxis, or inactivity without neophobia (defined by the corner 
index test described below) and died as early as 1 month 
of age. A few mice died immediately after a witnessed 
tonic-clonic seizure. The majority of Tg(HuAPP69s.TRImyc) 
and Tg(MoAPP.WT) animals overexpressing APP died 
after they were formally diagnosed by corner index criteria 
but prior to appearing moribund. These mice probably died 
suddenly, since most were found dead within 2-16 hr of 
having been examined for neophobia, where they per- 
formed poorly but were not obviously moribund. Gross 
and microscopic examinations of 6 Tg(HuAPPe9s.TRImyc) 
mice found dead revealed normal appearance, size, and 
regional development of the brain, with characteristic glio- 
tic brain pathology (described below) but no amyloid or 
evidence of microscopic or gross pathology outside the 
CNS. The cause of sudden death in these mice is unknown 
but may be related to seizures or neurogenic arrythmias. 
Behavioral Abnormalities 
Neophobia and Other Neurologic Signs 
In some Tg mice, we noticed an unusual behavior charac- 
terized by transient cessation in exploratory activity spe- 
cific to testing in a novel chamber. To study this behavior 
quantitatively, we devised a simple behavioral test, the 
corner index test, that revealed a striking difference be- 
tween Tg and non-Tg mice. Corner index scores for non-Tg 
mice showed few values < 1 during the first 3 months, 
while scores of some Tg mice overexpressing APP 
showed values _< 1 with advancing age, The low scores 
appear to reflect a neophobic response because no differ- 
ences in locomotor activity or exploratory motivation be- 
tween non-Tg and Tg mice were detectable in Y maze 
performance (described below). Based on >2000 tests of 
>100 Tg mice and >2500 tests of >140 non-Tg mice <150 
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Figure 3. Survival in 3 Lines of FVB/N Mice Overexpressing APP 
Kaplan-Meier survival curves for Tg(HuAPP69s.WTmyc)6209 (top), 
Tg(HuAPP~9~.TRImy¢)1118 (middle), and Tg(HuAPP69s.SWE)2123H 
(bottom) are shown. Calculations include animals that were removed 
from the study for analysis in addition to long-term survivors. The 
curves illustrate the occurence of long-term survivors among Tg lines 
overexpressing APP in spite of early death in a proportion of each 
line. For Tg(HuAPP69s.WTmyc)6209, 3 mice survived over 350 days, 
with the oldest (2) currently 605 days old. The oldest surviving mice 
from the Tg(HuAPP~gs.TRImyc)1118 and Tg(HuAPP69s.SWE)2123H 
lines are 375 and 191 days of age. Results to date suggest hat the 
risk of death for Tg mice surviving longer than 200 days does not differ 
significantly from that for non-Tg mice. 
days of age, the age when two scores of "0" or a "0" and 
"1" appeared within three consecutive testing sessions de- 
fined the onset of neophobia. None of the 100 non-Tg mice 
tested through 100 days of age or of the 48 non-Tg mice 
tested through 150 days of age failed the corner index 
test. Neophobia developed as early as 1 month of age in 
both male and female Tg mice overexpressing APP and 
preceded death by an average of 40 days in Tg1130H 
mice. Six Tg FVB/N lines and 4 additional founders 
expressing high levels of wild-type MoAPP69~.WT, 
HuAPP69s.SWE, HuAPPe95.WTmyc, or HuAPPeg~.TRImyc 
exhibited neophobia (see Table 2). Mice failing the corner 
index test also exhibited other neurologic signs, including 
thigmotaxis, agitation, stiff tail, stare, tremulousness, and 
inactivity• Of 181 mice from affected lines, 6 had general- 
ized tonic-clonic seizures during corner index testing• To 
ensure that neophobia and early death were not artifacts 
of overexpression of a foreign (human) species of protein 
and to determine whether these abnormalities could be 
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Figure 4. Dependence of Death and Neophobia upon Transgenic 
Brain APP Expression, APP Genotype, and Host Strain 
(a) Death rates during the first 100 days of life were determined for Tg 
FVB/N mice (solid lines) expressing different levels of HuAPP89~.SWE 
(squares), HuAPP695.TRImyc (circles), HuAPP695.WTmyc (diamonds), 
and wild-type MoAPP (crosses) and for Tg C57B6 x (C57B6/SJL)F1 
mice (dashed line) expressing HuAPP695.SWE (triangles). For levels 
of APP expression >1, a larger fraction of mice died expressing 
HuAPP69s.TRImyc, HuAPP69s.SWE, or HuAPP69~.WTmyc than wild- 
type MoAPP, indicating that death rates are greater for mutant and 
wild-type HuAPP than for wild-type MoAPP, and that APP overexpres- 
sion per se is not the cause of death. Tg(HuAPP69~.SWE)C57B6 x
(C57B6/SJL)F1 mice exhibited significantly lower rates of mortality 
than Tg FVB/N mice expressing either HuAPP69s.TRImyc or HuAPP6g~. 
SWE, demonstrating a pronounced effect of host strain on mortality. 
The Tg APP level in Tg FVB/N mice expressing HuAPP895.SWE was 
interpolated using information shown in Figure 2 and known Tg copy 
numbers; too few mice were generated, owing to poor breeding behav- 
ior and early death, to enable direct APP analyses. 
(b) The development of neophobia during the first 100 days was deter- 
mined for Tg FVB/N mice expressing different levels of HuAPP69~.TRI- 
myc (circles) and wild-type MoAPP (crosses). For levels of APP expres- 
sion >1, the occurrence of neophobia ishigher for Tg mice expressing 
HuAPP6~s.TRImyc. 
accelerated by endogenous MoAPP, we generated Tg 
FVB/N mice overexpressing wild-type MoAPP; 37% of 
Tg1855 and 54% Tg1874 mice were neophobic at 100 
days, and 11% of Tg1874 mice were dead at 100 days 
(see Table 2). The rate of development of neophobia was 
lower in Tg mice expressing MoAPP69s.WT than in Tg mice 
expressing HuAPP695.TRImyc, paralleling the lower death 
rates in Tg(MoAPP69s.WT) mice (Figure 4b). 
To determine whether non-Tg FVB/N mice, with an aver- 
age lifespan of 2 years, become behaviorally impaired with 
advancing age, 110 FVB/N mice 150-500 days of age 
from three different institutions (University of Minnesota, 
Minneapolis, Minnesota; McLaughlin Research Institute, 
Great Falls, Montana; Harlan Sprague Dawley, Inc., India- 
napolis, Indiana) were studied for behavioral abnormali- 
ties. With advancing age, 15 mice of both sexes developed 
neophobia (defined by the corner index test) along with 
agitation and inactivity as early as 1 54 days of age, 3 had 
seizures, several died prematurely (excluding mice sacri- 
ficed for studies), and 6 mice died from tumors or acciden- 
tally. One death occurred immediately following a seizure; 
the other mice died suddenly of unknown causes. Several 
neophobic mice grew progressively less active and were 
sacrificed between 9 and 91 days after the onset of the 
disorder. The cumulative incidence of neophobia in this 
cohort of FVB/N mice was -20% by 500 days of age. 
Impa i red  Spat ia l  A l te rnat ion  in Tg FVB/N Mice  
Tg FVB/N mice were assessed for spontaneous alterna- 
tion behavior in a Y maze, a task thought to involve the 
hippocampus (Douglas, 1990). Neophobia in Tg mice ex- 
pressing either MoAPP695.WT or HuAPP695.TRImyc was 
associated with diminished spontaneous alternation (Fig- 
ures 5b and 5e). (Mice overcame neophobia in the Y maze 
during the initial 5 min free exploration interval.) There 
was no significant difference in the number of maze arm 
entries made by 24 neophobic Tg (39.9 __ 6.44, mean _+ 
SEM) and 24 age-matched non-Tg (45.8 _+ 5.61) mice, 
indicating that potential differences in locomotor activity 
and exploratory motivation cannot explain the different 
rates of spontaneous alternation. Impaired spontaneous 
alternation was observed in Tg(HuAPP69~.TRImyc) mice 
not yet neophobic by corner index criteria but already 
showing signs of slowness and thigmotaxis (Figure 5d), 
indicating that impaired spatial alternation precedes neo- 
phobia. No significant difference was observed between 
9-week-old Tg(MoAPP69s.WT) mice showing signs of inac- 
tivity and thigmotaxis, but not yet neophobic by corner 
index criteria, and non-Tg littermates (Figure 5a); however, 
the relatively low scores obtained by both experimental 
and control subjects in this experiment may have obscured 
a difference. Five-week-old Tg(HuAPP6%.TRImyc) mice 
exhibiting no clinical abnormalities showed no impairment 
of spatial alternation compared with non-Tg littermates 
(Figure 5c), obtaining significantly higher scores than 8- 
or 11-week-old Tg mice (p = .0432, t test), indicating that 
abnormal spatial alternation in Tg FVB/N mice overex- 
pressing APP is an acquired trait. 
Regional  Cerebral  G lucose Uti l ization 
To identify the affected areas of the brain in neophobic 
Tg and neophobic mid- to late-adult non-Tg FVB/N mice, 
regional brain glucose utilization was determined by densi- 
tometric measures of [~4C]deoxyglucose l vels (l~Ci/100 
g/min). Regional cerebral glucose utilization in neophobic 
Tg1130H and age-matched non-Tg mice was compared. 
The former possess significant reductions in glucose utili- 
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Tg(HuAPP695.TRImyc)1140 transgene-positive neophobic mice (dagger) and 
Figure 5. Impaired Spontaneous Alternation 
in a Y Maze 
The values shown represent the percentage 
alternation during an 8 min period (mean -+ 
SEM). The following roups were tested: (a) 11 
Tg(MoAPP69~.WT)1874 transgene-positive mice 
showing signs of inactivity but not yet meeting 
criteria for neophobia nd 11 transgene-nega- 
tive littermates (9 weeks old); (b) 11 Tg(Mo- 
APP69~.WT)1874 transgene-positive n opho- 
bic mice (dagger) and 12 transgene-negative 
littermates (t5 weeks old); (c) 6 Tg(HuAPPB95.- 
TRImyc)1130H and 4 Tg(HuAPP69~.TRImyc)- 
1140 transgene-positive mice showing no ab- 
normal neurologic signs and 15 transgene- 
negative littermates (5 weeks old); (d) 12 
Tg(HuAPP69~.TRImyc)1130H transgene-pos- 
itive mice showing signs of inactivity but not 
yet meeting criteria for neophobia and 12 
transgene-negative littermates (8 weeks old); 
and (e) 5 Tg(HuAPP695.TRImyc)1130H and 7 
12 transgene-negative littermates (11 weeks old). Two 
Tg(MoAPP69~.WT)1874 transgene-positive mice were excluded because they made too few entries (<12) to determine an accurate alternation 
score. Differences between transgenic and nontransgenic mice were compared using a two-tailed Student's t test (single asterisk, p < .05; double 
asterisk, p < .01). 
zation in various cortico-limbic regions, including the ento- 
rhinal cortex (-37%; p = .008), hippocampus (-30%; 
p _< .003), and amygdala (-28%; p = .004) as well as 
the parietal (-34%; p = .001 ), temporal (-33%; p = .017), 
and occipital (-36%; p = .001) lobes of the cerebral cortex 
(Table 3; Figure 6). The somatosensory-motor cortex was 
relatively spared, corroborating the apparent absence of 
motor and sensory abnormalities in these mice, and many 
brain stem regions, including the pontine reticular forma- 
tion, vestibular nuclear complex, and dentate nucleus, 
showed no significant reduction in glucose utilization. 
Comparisons of regional brain glucose utilization in neo- 
phobic mid- to late-adult non-Tg FVB/N mice compared 
with behaviorally normal, age-matched FVB/N mice re- 
vealed significant decreases in regional glucose utilization 
in several areas of the cerebrum, particularly the entorhi- 
nal cortex (-45% ; p < .001), hippocampus (-33%; p < 
.001), amygdala (-30%; p = .003), hypothalamus (-34%; 
p = .004), and caudate-putamen (-14%, p < .001), as 
well as the parietal (-16%; p = .027) and temporal (-17%; 
p = ,019) lobes of the cerebral cortex. In contrast, no 
significant decreases were observed in brainstem struc- 
tures (p > .05), with the exception of the inferior colliculus 
(-22%; p = .015). The somatosensory-motor cortex was 
notably less affected, as in neophobic Tg FVB/N mice. 
The pattern of regional brain glucose utilization in Tg mice 
overlapped strikingly with that of aged, impaired non-Tg 
mice. With the sole exception of the inferior colliculus, 
every affected area in aged, impaired non-Tg mice was 
also significantly reduced in the younger Tg mice. 
Astrogliosis without Amyloid Formation in Brains 
of Transgenic FVB/N Mice 
Using coded specimens, we examined brains of 19 neo- 
phobic Tg mice expressing HuAPP69s.SWE, HuAPP895.W- 
Tmyc, HuAPP695.TRImyc, or MoAPP69~.WT as well as 12 
age-matched, unaffected non-Tg mice (see Table 2). Fif- 
teen brains from affected Tg mice exhibited prominent 
hypertrophic astrocytes located predominantly inthe para- 
hippocampal area, hippocampus, amygdala, and cerebral 
cortex (Figure 7a), with relative sparing of the basal gan- 
glia. The astrocytes had enlarged, elongated processes 
when immunostained for glial fibriliary acidic protein (GFAP), 
and there was no apparent increase in the number of 
astrocytes. Brains of age-matched non-Tg mice were de- 
void of reactive gliosis. In general, there was an associa- 
tion between gliosis and abnormal behavior (Yates- 
corrected X~ = 14.83, p = .00012). Bielschowsky silver 
stains revealed no neurofibrillary tangles, dystrophic neu- 
rites, or neuritic plaques. Neurons appeared normal with 
Nissl and hematoxylin and eosin stains. 
Seven non-Tg FVB/N mice 9-12 months of age exhib- 
iting neophobia and 9 age-matched, behaviorally normal 
mice were examined in a coded fashion. Six of the 7 brains 
from neophobic mice exhibited pronounced astrocytic gli- 
osis in the hippocampus, parahippocampal area, amyg- 
dala, and cerebral cortex as detected by GFAP staining 
(Figure 7c). The neostriatum showed little or no astro- 
cytosis. None of the brains from the 9 age-matched, behav- 
iorally normal mice exhibited this degree of gliosis, al- 
though modest gliosis restricted to the hippocampus was 
observed in some control FVB/N mice. These findings indi- 
cate that neophobia in non-Tg FVB/N mice is associated 
with gliosis in the cerebral cortex and limbic brain regions 
(Yates-corrected ~2 = 8.96, p = .003). The brains of these 
mice showed no amyloid deposition, neurofibrillary tan- 
gles, neuronal abnormalities, or qualitative changes in 
neuronal or glial numbers. To detect APP or AI3 immunore- 
activity in brain tissue from animals with clinical abnormali- 
ties in Tg FVB/N lines overexpressing HuAPP, we used 
two antibodies: 8E5 antibody, which stained amyloid and 
intraneuronal vesicular structures in microwaved tissue 
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Figure 6. Regional Brain Glucose Hypo-Utilization in Transgenic Mice 
(a) Coronal sections through cerebral cortex, hippocampus, and ante- 
rior brainstem of a neophobic Tg(HuAPP69s.TRImyc) 1 130H mouse and 
a non-Tg littermate. Optical density ratios were color coded. Blue and 
black represent lowest optical density ratios; red and white represent 
highest optical density ratios. 
(b) Enlarged view of hippocampus and overlying cerebral cortex show- 
ing diminished glucose utilization in both regions in the Tg mouse. 
(c) Coronal sections through cerebellum and posterior brainstem 
showing no diminution in glucose utilization in Tg mouse. 
sections from patients with AD, and 6E10 antibody, which 
stains amyloid from patients with AD only after formic acid 
pretreatment of brain tissue. In 4 Tg(HuAPP69~.SWE) mice 
and 7 Tg(HuAPP695.TRImyc) mice, neither the microwave 
nor formic acid pretreatment of brain tissue revealed extra- 
cellular APP or AI5 immunoreactivity using these antibod- 
ies. Amyloid deposits were not demonstrable by staining 
with Congo red or thioflavin S. We concluded that the 
abnormal phenotype in these Tg mice occurred indepen- 
dently of amyloid plaque deposition. 
Host Strain Effect upon Mortality in Transgenic 
Mice Overexpressing APP 
To assess effects of host strain upon mortality in Tg mice 
expressing HuAPP transgenes, animals were created in 
(C57B6/SJL)F1 embryos backcrossed to C57B6 breeders. 
We examined 28 Tg mice from Tg(HuAPP69~.SWE)C57- 
B6 × C57B6/SJL-2576 mice expressing HuAPP with the 
Swedish mutation at a level >4-fold over that of endoge- 
nous brain APP (higher than in any Tg FVB/N lines overex- 
pressing APP). These mice bred well and showed no differ- 
ence in death rates when compared with 39 non-Tg 
littermates (see Figure 4a). Three Tg and 2 non-Tg mice 
died within the first 4 months of unknown causes. Ten 
Tg2576 mice appear well at 8 months of age, having out- 
lived all i3 Tg FVB/N mice from 4 founders harboring - 40 
copies of the HuAPP695.SWE transgene with an estimated 
2-fold overexpression of Tg APP. 
Discussion 
FVB/N mice overexpressing mutant and wild-type APP 
transgenes die early and possess clinical abnormalities, 
including impaired spatial alternation, neophobia, agita- 
tion, inactivity, seizures, diminished regional brain glucose 
utilization, and hypertrophic astrogliosis in the cerebrum 
without amyloid plaques. We have identified three param- 
eters that influence the development of clinical abnormali- 
ties in Tg mice expressing APP: levels of APP expression, 
primary structure of APP transgenes, and host strain. 
C57B6 x (C57B6/SJL)F1 hybrid mice overexpressing mu- 
tant HuAPP live significantly longer than FVB/N mice ex- 
pressing the same Tg APP, demonstrating a host strain 
effect upon the resultant phenotype. The clinical abnor- 
malties in Tg FVB/N mice closely resemble those oc- 
curring in a subset of older non-Tg FVB/N mice, sug- 
gesting that overexpression of APP accelerates anaturally 
occurring, age-related CNS disorder in this strain of mice. 
Transgenic APP Expression 
Until overexpression of APP and APP fragments was 
achieved, there were no reports of robust clinical or patho- 
logical phenotypes in multiple lines of Tg mice (Sandhu 
et al., 1991; Yamaguchi et al., 1991; Kammesheidt et al., 
1992; Buxbaum et al., 1993; Lamb et al., 1993; Pearson 
and Choi, 1993). Some transgenic mice have been re- 
ported with rare AI3 deposits and age-related memory defi- 
cits (Quon et al., 1991; Higgins et al., 1994; Moran et al., 
1995). Neuronal apoptosis associated with seizures and 
death was observed in Tg FVB/N mice overexpressing 
cytoplasmic AI~ (LaFerla et al., 1995), and abundant cere- 
bral amyloid deposition was reported in Tg mice express- 
ing mutant HuAPP exceeding endogenous levels by 5- 
10 times (by qualitative Western blot; Games et al., 1995). 
Tg APP expression in our mice with the highest APP levels 
was comparable to that in mice described by Games et 
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Table 3. Regional Brain Glucose Utilization Index in Healthy versus Neophobic Aged FVB/N Mice and in Healthy Nontransgenic versus 
Neophobic FVB/N Mice 
Aged Aged Non-Tg Tg 1130H 
Brain Healthy Neophobic t Test Healthy Neophobic t Test 
Regions (mean ± SEM) (mean ± SEM) (p) (mean ± SEM) (mean ± SEM) (p) 
CxE" 1.32 ± 0.12 0.73 - 0.08 <.001 1.08 _+ 0.09 0.68 + 0.06 .008 
HpA a 1.13 ± 0.06 0.76 ± 0.04 <.001 1.05 - 0.06 0.73 ± 0.06 .003 
HpP" 1.05 _ 0.03 0.86 ± 0.01 <.001 1.10 ± 0.06 0.79 ± 0.05 .002 
CP a 1.32 ± 0.03 1.13 ± 0.03 <.001 1.33 ± 0.08 1.09 ± 0.05 .048 
Amg a 0.79 ± 0.05 0.55 ± 0.05 .003 0.74 ± 0.04 0.53 -+ 0.05 .004 
Ht a 0.71 ± 0.07 0.47 ± 0.05 .004 0.74 _+ 0.04 0.58 ± 0.04 .015 
IC 1.38 ± 0.13 1.07 ± 0.02 .015 1.61 ± 0.06 1.58 ± 0.12 NS 
CxT a 1.09 ± 0.08 0.90 ± 0.05 .019 1.10 ± 0.08 0.74 ± 0.11 .017 
CxP" 1.52 ± 0.06 1.27 ± 0.11 .027 1.34 ± 0.07 0.88 ± 0.08 .001 
SC 1.31 ± 0.06 1.18 ± 0.07 NS 1.26 ± 0.06 0.94 ± 0.07 .003 
GP 0.80 ± 0.08 0.68 ± 0.03 NS 0.96 ± 0.09 0.61 ± 0.06 .013 
TV 1.49 ± 0.09 1.30 ± 0.18 NS 1.24 ± 0.06 0.83 ± 0.08 .002 
HM 0.96 ± 0.05 1.01 ± 0.04 NS 1.05 ± 0.05 0.97 ± 0.01 NS 
CxO 1.31 ± 0.09 1.21 ± 0.08 NS 1.23 ± 0.05 0.79 ± 0.09 .001 
PRF 0.87 ± 0.08 0.84 ± 0.08 NS 0.97 ± 0.04 0.91 _+ 0.04 NS 
cc 0.59 ± 0.07 0.51 _+ 0.06 NS 0.84 - 0.06 0.71 ± 0.08 NS 
CxF 1.37 _+ 0.06 1.28 ± 0.12 NS 1.37 ± 0.08 1.14 ± 0.08 NS 
VC 1.50 ± 0.08 1.58 ± 0.22 NS 1.52 ± 0.07 1.45 ± 0.06 NS 
TA 1.61 ± 0.07 1.51 ± 0.17 NS 1.42 ± 0.10 1.03 ± 0.07 .010 
TR 1.45 ± 0.09 1.39 ± 0.13 NS t.37 ± 0.06 0.95 ± 0.09 .002 
CxSM 1.53 ± 0.06 1.46 ± 0.19 NS 1.36 ± 0.11 1.15 _+ 0.07 NS 
SN 0.92 ± 0.03 0.91 ± 0.03 NS 0.99 ± 0.06 0.76 -+ 0.06 .018 
DN 1.11 ± 0.09 1.12 ± 0.12 NS 1.20 _+ 0.05 1.17 ± 0.04 NS 
VM 1.07 ± 0.05 1.11 ± 0.01 NS 1.24 ± 0.04 1.14 ± 0.03 NS 
Neophobic animals were identified by the corner index test. For each animal, glucose utilization within every brain region was normalized to the 
whole cerebellar value, since the cerebellum was devoid of clinical and pathological abnormalities. Statistical analyses between age-matched 
aged mice and age-matched non-Tg and Tg mice were performed using an unpaired Student's t test (NS, not significant, p > .05). Average ages 
for aged healthy, aged neophobic, non-Tg healthy, and Tg1130H neophobic mice were 429.3 - 39.3 (n = 4), 429.3 _+ 39.3 (n = 4), 98.1 _+ 
13.9 (n = 8), and 84.5 ± 4.74 (n = 6), respectively. 
a Brain regions with significantly diminished glucose utilization indices in both aged and Tg impaired mice. 
CxE, entorhinal cortex (also called parahippocampal area); HpA, anterior hippocamput (containing CA1-3 fields); HpP, posterior hippocampus; 
CP, caudate-putamen (also called striatum); Amg, amygdala; Ht, hypothalamus; IC, inferior colliculus; CxT, temporal cortex; CxP, parietal cortex; 
SC, superior colliculus; GP, globus pallidus; TV, ventral thalamic nucleus; HM, cerebellar hemisphere; CxO, occipital cortex; PRF, pontine reticular 
formation; cc, corpus callosum; CxF, frontal cortex; VC, vestibular nuclear complex; TA, anterior thalamic nucleus; TR, thalamic reticular nucleus; 
CxSM, somatosensory-motor cortex; SN, substantia nigra; DN, dentate nucleus; VM, cerebellar vermis. 
al. All our Tg FVB/N lines expressing supra-endogenous 
levels of Tg APP  developed clinical abnormal i t ies within 
the first 100 days of life. 
Three observat ions argue against the abnormal  pheno- 
type in our Tg mice being due to a nonspecif ic effect of 
Tg protein overexpression.  First, the onset  of neophobia 
and the age at death were inf luenced by specif ic transgene 
genotypes:  mutant  HuAPP conferred the disorder with 
higher age-related penetrance than wild-type MoAPP for 
similar levels of expression. Second, the total burden of 
brain APP  in some affected Tg lines was only twice endog- 
enous levels. Even in animals that expressed >4 times 
the normal level of APP,  the unchanged levels of brain 
PrP, which like APP  undergoes processing through the 
secretory pathway,  argues against a nonspecific effect of 
mere protein overexpress ion taxing the cellular machinery 
for mRNA processing, protein sythesis, or protein modifi- 
cation. Third, Tg FVB/N mice harboring hamster  PrP cos- 
mid transgenes overexpress ing PrP with a mutat ion l inked 
to Gerstmann-Str~_uss ler -Scheinker  d isease (GSS), a 
dominant ly inherited neurodegenerat ive disorder, develop 
an entirely distinct phenotype with ataxia and spongiform 
degenerat ion (T. Haga and S. Prusiner, personal commu-  
nication). 
The absence of changes in endogenous mouse PrP lev- 
els between Tg and non-Tg mice also makes it unlikely 
that an artifact of supernumerary  t ransgenes resulted in 
competit ive inhibition of PrP transcription factors. In addi- 
tion, a previously published line of Tg FVB/N mice express- 
ing human PrP driven by equivalently high or higher 
t ransgene copies of the hamster  PrP gene cosmid vector 
exhibited none of the behavioral  or pathological abnormal-  
ities observed in Tg APP  mice (Telling et al., 1994), 
weighing against  nonspecific effects of the 5'or 3'untrans- 
lated regions in the PrP cosmid vector or other PrP gene 
components. 
Primary Structure of APP 
The distinction between age-dependent penetrance of 
death and neophobia for FVB/N mice expressing MoAPP 
and HuAPP transgenes indicates that APP  transgenes 
with different amino acid sequences differ in their age- 
dependent  potency as regards the effect. However,  the 
qualitative features of the phenotype we observe in all Tg 
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Figure 7. Cortico-Limbic Hypertrophic Astro- 
cytic Gliosis in Transgenic and Nontransgenic 
FVB/N Mice Exhibiting Neophobia and Inac- 
tivity 
Coronal sections of cortico-limbic and brain- 
stem structures reacted with antibody to GFAP 
show hypertrophic gliosis in cortico-limbic ar- 
eas of animals exhibiting behavioral bnormali- 
ties. C, cerebral cortex; H, hippocampus; M, 
midbrain. 
(a) Tg(HuAPP89s.TRImyc)1118-334 exhibiting 
behavioral abnormalities (agitation and neo- 
phobia) at 144 days of age, sacrificed at 206 
days. 
(b) Non-Tg littermate of Tg(HuAPP695•TRImyc) 
1118-334 without behavioral abnormalities, 
age 206 days• 
(c) Non-Tg #4565 exhibiting behavioral bnor- 
malities (inactivity and neophobia) at 324 days 
of age, sacrificed at334 days. 
(d) Non-Tg littermate of #4565 without behav- 
ioral abnormalities, age 334 days. 
I I  
FVB/N mice overexpressing APP resemble an accelera- 
tion of a naturally occurring CNS disorder in FVB/N mice, 
regardless of the primary structure of APP. Although it is 
possible that he presence of two additional transmem- 
brane mutations in HuAPP.TRImyc could diminish gener- 
ation of AI3, and thereby alter the phenotype, our data 
indicate that mice expressing this transgene are in fact 
able to generate both Al31-40 and AI31-42 and develop the 
same clinical abnormalities as Tg mice expressing HuAP- 
P695.SWE, HuAPP895.WTmyc, and MoAPP~9s.WT trans- 
genes. Given this consistent pattern of data, it is likely 
that FVB/N mice overexpressing other APP transgenes, 
including HuAPP.V7171 lacking the extra mutations, would 
also exhibit a phenotype resembling the naturally oc- 
curring CNS disorder described here in FVB/N mice. This 
hypothesis is being tested• 
Host Effects 
There are two important reasons to express APP and APP 
mutants in Tg mice: first, to model AD, and second, to 
study the biologic activity of APP overexpression in vivo. 
Such studies must consider the influence of the host on 
the Tg phenotype because numerous genetic and biologic 
differences exist between humans and mice. For example, 
host modification of a pathological phenotype occurred in 
GSS modeled in Tg mice. Overexpression of a mutant PrP 
genetically linked to GSS produced spongiform neurode- 
generation indistinguishable from murine scrapie, but the 
amyloid plaques that define GSS in humans occurred too 
infrequently to be seen in the majority of Tg mice (Hsiao 
et al., 1990, 1994; Prusiner and Hsiao, 1994). Another 
example of host modification has been described in FVB/N 
and (C57B6 x 129Sv)F1 mice harboring a disrupted kera- 
tin gene. When the disrupted keratin locus resides in 
(C57B6 x 129Sv)F1 mice, death during embryogenesis 
is observed, but in FVB/N mice, a mild skin disorder is 
observed (Baribault et al., 1994). We show here a third 
example of host modification of Tg phenotypes in FVB/N 
and C57B6 x (C57B6/SJL)F1 mice expressing the same 
mutant human APP transgene. When high levels of Hu- 
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Table 4. Transgenic Mice Overexpressing APP or A~ 
This Paper Games et al., 1995 LaFerla et al., 1995 Quon et al., 1991' 
Transgenic proteins Human APP Human APP Mouse A~-cytoplasmic Human APP 
Mouse APP (Mouse A~-secreted) b 
Transgene genotype Wild type, V717F Wild type Wild type 
K670N, M671L 
V7171, V721A, M722V 
Promoters PrP PDGF NF-L NSE 
APP isoforms 695 695, 751,770 NA 751 (695) ~ 
Highest brain Cerebrum Cerebrum Cerebrum Not reported 
expression Cerebellum Cerebellum 
Target cells Neurons Neurons Neurons Neurons 
Less in astrocytes 
APP levels Comparable to Games, 1995 -10x  (qualitative Western) NA Not quantified 
(qualitative Western) 
>8 x (ECL, densitometry) 
4.6x (~2Sl-protein A,
phosphorimagi ng) 
Transgenic A!3 Present Present Present Present by ICC e 
Behavioral phenotype Neophobia None reported Seizures Impaired spatial 
Impaired spatial alternation alternation in Y maze 
in Y maze Impaired spatial 
Agitation, inactivity memory in water 
Seizures maze 
Lifespan Early death (>50% by 1 year) d Not reported Early death (>50% by 1 No earlydeath reported 
year) 
Brain physiology Not reported Not reported Not reported Decreased glucose utilization 
in forebrain (especially entorhinal 
cortex, hippocampus, amygdala) 
Pathology Cortico-limbic gliosis Cortico-limbic amyloid Cortico-limbic gliosis Rare APP deposits 
Neuritic changes Apoptosis Tau immunoreactivity 
Extracellular A~ deposits 
Swiss Webster x (B6/D2)F1 FVB/N Mouse strain FVB/N JU 
a See also Higgins et al., 1994, and Moran et al., 1995. 
b No phenotypic abnormalities reported. 
No phenotypic abnormalities reported. 
d Tg mice expressing supra-endogenous levels of HuAPP or MoAPP. 
Detected by immunocytochemical nalysis. 
APP with the Swedish mutation were expressed in FVB/N 
mice, >70o of mice died by 100 days of age; however, 
<10% of C57B6 x (C57B6/SJL)F1 mice expressing higher 
levels of the same transgene died during the same age 
interval. It is very common for mutations to be too deleteri- 
ous to be maintained in standard inbred mouse strains. 
For instance, most inbred mice homozygous for the grey 
tremor mutation die by 3 months of age, but on outbred 
genetic backgrounds, many survive and reproduce (Kin- 
ney and Sidman, 1986). Therefore, it will be important 
both to distinguish the protean manifestations of Tg APP 
expression in different pure and hybrid strains of mice and 
to identify features occurring in common. It is possible that 
the specific features associated with Tg APP expression 
in FVB/N mice involve particular genes, which may be 
possible to identify through genetic analyses. The same 
approach may reveal the genes that are responsible for 
distinct phenotypes in various other inbred strains. 
The existence of long-term survivors in some Tg FVB/N 
lines overexpressing APP implies that other, as yet un- 
known factors besides APP levels, APP primary structure, 
and host strain can influence the phenotypes of individual 
Tg mice. In these Tg lines, the sharp drop in mortality after 
- 150-200 days implies that vulnerable periods exist in an 
animal's life, during which at least some of the deleterious 
effects of APP overexpression are more likely to manifest. 
We are exploring the possibility that extracellular AI3 de- 
posits are more likely to appear in long-term survivors 
since A~ deposits have been found only in older Tg mice 
expressing APP (Higgins et al., 1994; Games et al., 1995). 
Other Transgenic APP Paradigms 
A summary of four Tg paradigms overexpressing APP or 
AI~ is presented in Table 4. There are two apparent discrep- 
ancies between the clinical, neuropathologic, and func- 
tional appearances of our Tg FVB/N mice expressing 
mutant APP transgenes and the Tg mice with amyloid 
deposits (Games et al., 1995); our mice displayed behav- 
ioral and functional abnormalities, but lacked amyloid de- 
posits. Levels and regions of APP expression were compa- 
rable and cannot explain the different phenotypes. 
Whether the discrepant clinical and neuropathologic ap- 
pearances of our FVB/N mice expressing high levels of 
APP and the hybrid mice of Games et al. are due to host 
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strain differences or transgene disparities is under investi- 
gation. 
On the other hand, the similar clinical and pathological 
features in FVB/N mice overexpressing APP and cyto- 
plasmic A~ (LaFerla et al., 1995) support the importance 
of host influences upon Tg phenotypes. The differences 
between these Tg mice may be due to distinctions be- 
tween APP and AI3 expression and the cellular processing 
of these proteins, and to the respective levels of A~ 
achieved in different mice. It is possible that FVB/N mice 
develop a lethal CNS disorder without developing amyloid 
plaques because they are more sensitive to the neurotoxic 
effects of AI~ (or some other component of APP), causing 
them to die before AI3 forms fibrils and precipitates. FVB/N 
mice might also lack the extracellular substrate molecules 
or cells facilitating AI3 precipitation. Alternatively, FVB/N 
mice might efficiently clear extracellular AI3, impeding its 
aggregation to form plaques. 
It has been suggested that APP transgenes containing 
the KPI domain (APP751 and APP770) produce memory 
deficits, whereas transgenes without he KPI domain may 
not be effective in this regard (Moran et al., 1995). Tg 
mice described by Moran et al. expressing APPTsl were 
impaired in spatial alternation in a Y maze. Our Tg mice 
expressing APP transgenes lacking the KPI domain also 
exhibit impaired spatial alternation in a Y maze, indicating 
that, at least in FVB/N mice, this behavioral deficit can be 
induced by APP transgenes lacking the KPI domain. 
APP, Aging, and AD 
The CNS disorder in our Tg mice is directly related to 
overexpression of APP. Although the pathogenesis of the 
disorder appears to be due to act!vities of APP other than 
its ability to form extracellular amyloid deposits, it is still 
possible that AI3 mediates the pathogenic effects, since 
AI3 levels are elevated in Tg mice that develop neophobia 
and die. Murine AI3 secretion is enhanced in transfected 
murine cells expressing MoAPP (Araki et al., 1994), provid- 
ing a similar rationale for the development of the CNS 
disorder in Tg mice expressing high levels of MoAPP. 
Moreover, cytoplasmic murine AI3 is neurotoxic in vivo 
(LaFerla et al., 1995). It is possible that the naturally oc- 
curring senescent disorder in older FVB/N mice repre- 
sents a phenotypic continuum related to endogenous 
MoAPP expression. It will be critical to understand how 
aberrant APP metabolism can cause neuronal dysfunction 
without forming extracellular, congophilic aggregates. 
We have shown that Tg FVB/N mice overexpressing 
APP exhibit impaired spatial alternation in a Y maze. Poor 
performance in this task has been speculated to reflect 
diminished motivation to explore novelty, inattention, or 
failure to remember acquired information (Gerlai et al., 
1994). Since the task is believed to involve the hippocam- 
pus (Douglas, 1990), the significantly reduced levels of 
hippocampal glucose utilization in affected Tg mice cor- 
roborate the behavioral observation. Some other tradi- 
tional tests of spatial memory (e.g., Morris water maze; 
Morris, 1984) could not be used to test our mice because 
FVB/N mice have poor visual acuity (Taketo et al., 1991). 
We are continuing to study memory and learning behavior 
in these mice but do not know if it will be possible to devise 
other tests that will overcome this obstacle. We therefore 
elected to make a direct observation of brain function in 
these mice by studying the specific distribution of regional 
glucose hypo-utilization. 
The pattern of regional brain glucose hypo-utilization i
Tg mice overlapped strikingly with that of aged, impaired 
non-Tg mice. The differences that were observed, as in 
the occipital cortex, superior colliculus, substantia nigra, 
and thalamic nuclei, may reflect ectopic expression of Tg 
APP, trans-synaptic effects, or a more advanced stage of 
the disorder. Regions associated with learning, memory, 
and affective behavior, such as the association areas of 
the cerebral cortex, hippocampus, entorhinal cortex, and 
amygdala, are the regions most affected both in cogni- 
tively impaired, aged humans and patients with AD (de 
Leon et al., 1983; Kumar et al., 1991) and in impaired 
Tg FVB/N mice and aged, impaired non-Tg FVB/N mice. 
Notably, the greatest decrease in glucose utilization in 
both Tg mice and aged, impaired non-Tg mice was in the 
entorhinal cortex, which is among the earliest brain struc- 
tures involved in AD (Braak and Braak, 1991). Further- 
more, the somatosensory-motor cortex was relatively 
spared in both Tg mice and aged, impaired non-Tg mice, 
as it is in humans with AD. Yet both the parietal and tempo- 
ral lobes were significantly involved, as they are also in 
AD. Because we found no brain atrophy or neuronal oss, 
it is likely that glucose hypo-utilization i our mice reflects 
reduced glucose transport or metabolism rather than a 
reduction in the absolute number of neurons. A similar 
situation has been proposed in mildly demented AD pa- 
tients (Kumar et al., 1991) and in AD patients showing 
reduced levels of CNS-specific glucose transporters, inde- 
pendently of neuronal or synaptic loss (Simpson et al., 
1994). The remarkably analogous regional deficits in glu- 
cose utilization exhibited by humans with AD and FVB/N 
mice with both age- and APP-related brain impairment 
suggest that the disorders in humans and mice share at 
least some pathogenic mechanisms. 
Since APP overexpression accelerates an age-related 
CNS disorder in FVB/N mice, it is possible that aberrant 
APP expression in each species or strain would give rise 
to age-dependent CNS dysfunction characteristic for each 
type of animal. Senescence is associated with a variety 
of alterations in rodent brains (Finch, 1993). Amyloid de- 
posits and neurofibrillary tangles have not been docu- 
mented as naturally occurring age-associated processes 
in these species. Studies of aged, cognitively impaired 
rodents have shown gliosis (Landfield et al., 1977) and 
diminished regional brain glucose utilization in the cere- 
brum (Gage et al., 1984), indicating that age-related CNS 
dysfunction occurs in rodents without AI3 deposition. Cer- 
tain features of the age- and APP-related disorder ob- 
served in FVB/N mice appear to be distinctive for this 
mouse strain. The consistency with which the same neuro- 
logical phenotype was observed in older FVB/N mice and 
younger mice expressing mutant HuAPP or higher levels 
of wild-type MoAPP parallels the occurrence of AD in older 
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humans and younger individuals with mutant APP or 
higher levels of wild-type APP, as in Down's syndrome. 
Studies of the effect of aberrant APP expression on age- 
dependent CNS dysfunction in different genetic back- 
grounds, as well as other species, would confirm or refute 
this line of reasoning. 
Our studies indicate that age-dependent vulnerability of 
brain regions critical to learning, memory, and affective 
behavior in FVB/N mice can be accentuated by APP. How- 
ever, our mice lacked the classical histological features 
used by pathologists to diagnose AD in humans, amyloid 
plaques and neurofibrillary tangles, and yet they displayed 
behavioral, physiological, and neuropathological charac- 
teristics strikingly similar to those of a subset of aged 
non-Tg mice of the same strain. 
These data lead to the conclusion that APP overexpres- 
sion can accelerate or accentuate a senescent CNS disor- 
der in FVB/N mice without amyloid deposition in the brain. 
We speculate that some forms of senescence in the brains 
of other species may share a common biological origin 
with AD in humans. The histopathology of AD, particularly 
amyloid plaques, may thus be a useful diagnostic riterion 
for AD in humans but may not completely explain the 
pathogenesis of the human disorder. We suggest that the 
phenotypes of Tg animals expressing APP and other AD- 
associated genes (e.g., $182 and STM2) may be more 
completely understood if they are evaluated in the context 
of naturally occurring, age-dependent CNS dysfunction in 
the host and, when so understood, may cast further light 
upon the ultimate molecular and cellular abnormalities 
of AD. 
Experimental Procedures 
Transgene Construction 
The PrP-APP transgenes were generated by inserting Sail-flanked 
human or mouse APP OREs into a hamster PrP cosmid vector de- 
scribed in detail previously (Scott et al., 1992). This vector is a +40 
kb fragment of genomic DNA containing the hamster PrP gene with 
-20  kb of upstream sequences, in which the hamster PrP ORF is 
replaced by a unique Sail restriction site. The HuAPP+9~.SWE, 
HuAPP~9~.TRImyc, and HuAPP+9~.TRImyc APP sequences were modi- 
fied for strong translation initiation. The 5' end of the APP coding 
sequence is preceded by a Sail site and a strong Kozak translation 
initiation sequence (5'-GTCGACACCATGCTGCCC...), and the 3' end 
of the APP coding sequence is immediately followed by a Sail site 
(...AACTAGCAGCTG-3'; start and stop codons are underlined; site in 
boldface). These modifications and the APP mutations were made 
us=rig standard cloning methods and polymerase chain reacation 
(PCR)-based, site-directed mutagenesis. The PrP-APP cosmids were 
digested with Notl, which releases the PrP-APP fusion gene from the 
pcos6EMBL vector. The PrP-APP fusion genes were isolated after 
size fractionation on an agarose gel and electroeluted. The PrP-APP 
fusion gene was further purified with organic solvents and precipitated 
in ammonium acetate and ethanol. The PrP-APP fusion genes were 
dissolved in 5 mM Tris-CI (pH 7.4) or 10 mM Tris-CI (pH 8.0) to a 
final concentration of 2-4 ~g/ml prior to embryo injection. 
Transgenic Mouse Generation and Screening 
Transgenic lines were initiated by microinjection of single-cell mouse 
embryos as described (Hogan et al., 1986). Embryo donors and fertile 
studs were inbred FVB/N mice obtained from the National Cancer 
Institute (NIH). Post-weaning tail biopsy DNA was generated as de- 
scribed (Hanley and Merlie, 1991); 1 p.I of unpurified DNA was used 
in a 25 pl PCR reaction. To detect PrP-APP fusion DNA, the PrP- 
APP fusion DNA was amplified using the PCR with a pair of oligomer 
primers, 1503: (5'-CTGACCACTCGACCAGGTTCTGGGT-3') and 1502 
(5'-GTGGATAACCCCTCCCCCAGCCTAGACCA-3'), located in the 3' 
region of APP and the 3' untranslated region of PrP, respectively. The 
1503 primer recognizes a region that is homologous in mouse and 
human APP and could therefore be used to detect both PrP-MoAPP 
and PrP-HuAPP DNA. Using primers 1502 and 1501 (5'-AAGCGGCC- 
AAAGCCTGGAGGGTGGAACA-3'), a parallel PCR reaction ampli- 
fying a fragment of murine PrP was performed as a positive control. 
Transgene copy number analysis was performed using 5 pg of dena- 
tured purified tail DNA baked onto nitrocellulose and hybridized to a 
radiolabeled 1.3 kb SalI-Xhol DNA fragment encoding a segment of 
the hamster PrP 3' untranslated region located in the hamster PrP 
cosmid vector (Scott et al., 1992). After two high stringency washes, 
the relative intensities of signals from genomic DNAs of transgenic 
mice and hamsters were compared using a phosphorimager to obtain 
transgene copy numbers relative to diploid hamster genemic DNA. 
Analysis of Tranagene Expression 
APP transgene products were examined in progeny of transgenic 
founders sacrificed at 1-4 months of age. Quantitative immunoblotting 
of extracts from brain homogenates was carried out in parallel with 
extracts prepared from age-matched nontransgenic littermates. Ho- 
mogenates (20%, w/v) of brain tissues were prepared in TNE (50 mM 
Tris-CI [pH 8.0], 150 mM NaCI, 5 mM EDTA with 2% phenylmethylsul- 
fonyl fluoride) buffer using a hand-held polytron. Homogenates were 
diluted with an equal volume of TNE, 1% Nonidet P-40, 1% Deoxycho- 
late, 0.4% SDS and sonciated in a bath sonicater until all viscosity 
was lost. Homogenates were then boiled for 10 min and centrifuged 
at 10,000 x g for 10 rain. The supernatants were mixed with an equal 
volume of 2 x sample buffer (Laemmli, 1970), boiled 2 min, and frac- 
tionated using a 6% SDS-polyacrylamide gel. Proteins were electro- 
phoretically transferred to Immobilon membranes (Pierce) and incu- 
bated with monoclonal (22Cll and 6E10) anti-APP antibodies. 
Reactive monoclonal antibodies were visualized following incubation 
with secondary rabbit antibodies to mouse IgG before incubation with 
~2~l-protein A. Radioactivity was quantified on a phosphorimager (Mo- 
lecular Dynamics, Inc.). 
Analysis of AI~ in Brain Tissue 
Approximately 0.2 g of tissue was dounce homogenized (4 strokes) 
in 1 ml of 70% glass-distilled formic acid. Homogenates were centri- 
fuged at >100,000 x g for 1 hr. The formic acid extract (layered be- 
tween an overlaying lipid layer and a small pellet) was removed, and 
a small aliquot was diluted 50 times in 1 M Tris (pH 8.0). This sample 
was then further diluted 2.4 times in Buffer EC (0.02 M sodium phos- 
phate [pH 7.0], 0.2 mM EDTA, 0.4 M NaCI, 0.2% bovine serum albu- 
min, 0.05% CHAPS, 0.4% Block-Ace, 0.05% sodium azide), and 100 
t~1 of this was analyzed directly using either the Ban50/Ba27 or Ban50/ 
Bc05 ELISA systems described previously (Suzuki et al., 1994; Grav- 
ina et al., 1995). AL5 values reported were obtained by comparing the 
absorbance obtained from duplicate samples to standard curves of 
either AI3~-40 (Ban50/Ba27) or A~, 42 (Ban50/Bc05) obtained from 
Bachem. These values were corrected for dilution and initial wet weight 
of the tissue and are expressed as picomoles per gram of wet weight. 
All samples were coded with respect to the transgenic status of the 
animals. 
Behavioral Analyses 
Neophobia 
To perform the corner index test, a test mouse held by the tail is placed 
in the center of a cage (18 x 30 x 13 cm) with clean bedding (soiled 
bedding removed between tests), and the number of times the mouse 
sniffs the corners of the test cage during the first 30 s after being 
placed into the cage is recorded as the corner index (CI). Animals are 
usually tested 3 times per week. Low scores in animals housed alone 
were excluded from the analysis unless they displayed thigmotaxis or 
the characteristic freezing posture of other neophobic Tg mice. To 
control for variations in diurnal activity, all animals were tested between 
1300 hr and 1830 hr. Criteria for the presence of neophobia in non-Tg 
mice >150 days of age was _>3 consecutive scores of 0. 
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Spontaneous Alternation in a Y Maze 
The apparatus was a symmetrical Y maze. Each arm measured 8 x 
40 cm with 15 cm high side walls. The floor of the maze was open to 
allow a change of paper between each subject. Mice were placed in 
the center of the maze and allowed to explore freely for 5 min. Arms 
were arbitrarily designated A, B, and C, and the sequence of arm 
entries made in an 8 min period was used to measure alternation 
behavior: percentage alternation is the number of triads containing 
entries into all three arms (all three letters) divided by the total number 
of alternation opportunities (total number of arms entered - 2). Mice 
were coded and tested in random order. 
Pathological Analyses of Mice 
Brains of mice exhibiting behavioral abnormalities or found dead and 
age-matched littermates were examined for neuropathologic abnor- 
malities. Brains were immersion fixed or perfused with 10% phos- 
phate-buffered formalin or 4% buffered paraformaldehyde, mbedded 
in paraffin, and cut into 5-8 p.m sections. Tissue sections were stained 
with hematoxylin and eosin, cresyl violet, thioflavin S, or Congo red 
stains, or by using the 8ielschowsky silver methods. 
For immunohistologic studies, endogenous peroxidase was quenched 
by treatment with 6% hydrogen peroxide in methanol or with 3.0% 
hydrogen peroxide in methanol (1:5). To enhance APP antigen detec- 
tion, selected sections were microwave irradiated in water at full power 
for 15 min, cooled to room temperature, transferred to deionized water 
in 0.5 M TBS (pH 7.6), and pretreated with 0.4% Triton X-10O in TBS 
(TX/TBS), followed by 3% normal goat serum in TBS. Primary antibod- 
ies 6E10 (1:100) and 8E5 (1:100 ascites fluid) were prepared in 0.1O/o 
TX/TBS with 2% normal goat serum. Following incubation for 24 hr, 
slides were incubated in goat anti-rabbit or anti-mouse IgG (1:20) in 
0.1% TXfTBS, followed by a 1 hr incubation in rabbit or mouse peroxi- 
dase-antiperoxidase (1:100) at room temperature. Rinsed slides were 
reacted in the presence of 0.05% diaminobenzidine in 0.01% hydro- 
gen peroxide. Representative sections were silver enhanced ac- 
cording to the Fontana-Masson method (Masson, 1928). Other sec- 
tions were immersed in 70% formic acid for 10 min, rinsed in PBS, and 
immersed in 10% normal horse serum for 1 hr. Following incubation 
overnight at 4°C with primary antibody 6E10 (1:5000), sections were 
rinsed in PBS and incubated with anti-mouse IgG, followed by avidin- 
biotin complex (Vector Labs, Inc). Rinsed slides were reacted with 
diaminobenzidine and counterstained with Harris hematoxylin. GFAP 
was detected using a monoclonal antibody to porcine GFAP (Sigma). 
Regional Brain Glucose Utilization Analysis 
Mice received an intraperitoneal injection of [~4C]2-deoxyglucose (New 
England Nuclear; 5 i~Ci in 0.4 ml of 0.9% NaCI) and were sacrificed 
60 rain later. Brains were rapidly removed and frozen in isopentane 
cooled to 30 °C with dry ice. A sample of trunk blood was collected and 
used for determination of plasma glucose concentration by a glucose 
analyzer (Beckman). Techniques for quantitative autoradiography 
have been described in detail previously (tadecola et al., 1983; lade- 
cola and Xu, 1994) and are only summarized. Coronal brain sections 
(20 p_Lm) were cut on a cryostat (Hacker-Bright), mounted on glass 
slides, and apposed to X-ray film (Dupont) together with calibrated ~4C 
standards (ladecola et al., 1983). The film was developed 10 days later 
using an automatic developer (Kodak), and the optical density (OD) of 
regions of interest was determined bilaterally on four adjacent sections 
using a computerized image analyzer (MCID system, Imaging Re- 
search Inc.). OD was transformed into '"C concentration (nCi/g) using 
the standards on the film. Owing to the small size of some mice (15- 
20 g), blood sampling for determination of the 2-deoxyglucose arterial 
time course could not be perfomed, except at the time of sacrifice. 
Therefore, a CGU index was obtained by dividing regional radioactivity 
values (nCi/100 g/min) by the radioactivity of a region devoid of pathol- 
ogy, the whole cerebellum. This normalization procedure has been 
validated and widely used in small laboratory animals (e.g., Sharp et 
al., 1983; Mitchell and Crossman, 1984; Williot et al., 1988). In our 
experiments, the rate of ~4C accumulation in cerebellum (nCi/100 g/ 
rain) and plasma glucose did not differ between control, aged, and 
transgenic mice. This finding indicates that the CGU index provides an 
accurate estimate of glucose utilization as determined bythe method of 
Sokoloff et al. (1977). 
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